Johnson GS, Li J, Beaver LM, Dashwood WM, Sun D, Rajendran P, Williams DE, Ho E, Dashwood RH. A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphane-treated colon cancer cells. Mol Nutr Food Res. 2017 Apr;61(4).
Ertem FU, Zhang W, Chang K, Dashwood WM, Rajendran P, Sun D, Abudayyeh A, Vilar E, Abdelrahim M, Dashwood RH. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. Int J Cancer. 2017 Jan 15;140(2):460-468.
Ertem F, Dashwood WM, Rajendran P, Raju G, Rashid A, Dashwood R. Development of a murine colonoscopic polypectomy model (with videos). Gastrointest Endosc. 2016 Jun;83(6):1272-6.
Rajendran P, Dashwood WM, Li L, Kang Y, Kim E, Johnson G, Fischer KA, Löhr CV, Williams DE, Ho E, Yamamoto M, Lieberman DA, Dashwood RH. Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon. Clin Epigenetics. 2015 Sep 18;7(1):102.
Kim E, Bisson WH, Löhr CV, Williams DE, Ho E, Dashwood RH, Rajendran P. Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors. Curr Top Med Chem. 2016;16(7):714-31.
Rajendran P, Kidane A, Yu TW, Dashwood M, Williams DE, Ho E, Dashwood RH. HDAC turnover, CtIP acetylation, and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates. Epigenetics. 2013 Jun;8(6):612-23.
Rajendran P and Dashwood RH. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clinical Epigenetics. 2011;3:4.
Rajendran P, Delage B, Dashwood WM, Yu TW, Wuth B, Williams DE, Ho E and Dashwood RH. Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Mol. Cancer. 2011 May 30;10(1):68.
Rajendran P, Williams DE, Ho E, Dashwood RH. Metabolism as a key to histone deacetylase inhibition. Crit. Rev. Biochem. Mol. Biol. 2011;46(3):181-99.
Rajendran P, Jaggi M, Singh MK, Mukherjee R, Burman AC. Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Invest New Drugs. 2008 Feb;26(1):25-34.
Jaggi M, Prasad S, Singh AT, Praveen R, Dutt S, Mathur A, Sharma R, Gupta N, Ahuja R, Mukherjee R, Burman AC. Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors. Invest New Drugs. 2008 Dec;26(6):489-504.
Mukherjee R, Jaggi M, Rajendran P, Siddiqui MJ, Srivastava SK, Vardhan A, Burman AC. Betulinic acid and its derivatives as anti-angiogenic agents. Bioorg Med Chem Lett. 2004 May 3;14(9):2181-4.
For a complete list of publications, please visit: http://www.ncbi.nlm.nih.gov/pubmed/?term=rajendran+praveen